Grant: CIHR Fellowship
Direct Payment
$150,000.00
Molecular mechanisms of necroptosis, a novel cell death pathway to overcome drug resistance in childhood leukemia
EF 2012-13
Résumé
Acute lymphoblastic leukemia (ALL) accounts for almost 40% of childhood cancers diagnosed in Canada each year. Despite impressive survival rates of upwards of 90%, the sheer numbers of cases still makes leukemia the most likely cause of cancer related death in Canadian children. In ALL patients where current generation chemotherapies fail, cancer cells become resistant to cell death, which is normally induced by these drugs. Understanding what factors determine susceptibility to cell death is key to understanding drug resistance in ALL, and cancer at large.
The leukemia research group at the University Children's Hospital Zurich, has for the first time established a biobank of primary human ALL cells for laboratory study, which reflects the cross-section of ALL cancers from drug-susceptible to drug-resistant cases. Using this biobank, they have discovered that a new cancer drug (obatoclax) can resensitize aggressive drug resistant ALL cells to a standard chemotherapy drug (dexamethasone). Fascinatingly, this double drug treatment caused ALL cells to die through an only recently discovered pathway of cell death, known as necroptosis. Unlike apoptosis, a much better known form of programmed cell death, necroptosis occurs rapidly in what has been likened to cell explosion.
Necroptosis is known to be activated by the assembly of a large complex of proteins termed the necrosome. This research project aims at understanding the regulation and function of the necrosome in ALL cells. Through various advanced techniques, we will examine how the necrosome is formed, what signals are needed, and how cancer cells avoid this type of death normally. By studying necroptosis in ALL cells upon drug treatment, we may also be able to identify how it is regulated in other cancers as well. Ultimately, the hope of this type of research is that necroptosis could represent a new Achille's heel for aggressive drug resistant cancers, opening the door to new approaches for treatment.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Switzerland
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
282422
Name
McComb Scott R
Country
Switzerland
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Molecular mechanisms of necroptosis, a novel cell death pathway to overcome drug resistance in childhood leukemia
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Acute Lymphoblastic Leukemia; Apoptosis; Cancer Drug Resistance; Cell Death; Chemosensitization; Necroptosis
Abstract
Acute lymphoblastic leukemia (ALL) accounts for almost 40% of childhood cancers diagnosed in Canada each year. Despite impressive survival rates of upwards of 90%, the sheer numbers of cases still makes leukemia the most likely cause of cancer related death in Canadian children. In ALL patients where current generation chemotherapies fail, cancer cells become resistant to cell death, which is normally induced by these drugs. Understanding what factors determine susceptibility to cell death is key to understanding drug resistance in ALL, and cancer at large.
The leukemia research group at the University Children's Hospital Zurich, has for the first time established a biobank of primary human ALL cells for laboratory study, which reflects the cross-section of ALL cancers from drug-susceptible to drug-resistant cases. Using this biobank, they have discovered that a new cancer drug (obatoclax) can resensitize aggressive drug resistant ALL cells to a standard chemotherapy drug (dexamethasone). Fascinatingly, this double drug treatment caused ALL cells to die through an only recently discovered pathway of cell death, known as necroptosis. Unlike apoptosis, a much better known form of programmed cell death, necroptosis occurs rapidly in what has been likened to cell explosion.
Necroptosis is known to be activated by the assembly of a large complex of proteins termed the necrosome. This research project aims at understanding the regulation and function of the necrosome in ALL cells. Through various advanced techniques, we will examine how the necrosome is formed, what signals are needed, and how cancer cells avoid this type of death normally. By studying necroptosis in ALL cells upon drug treatment, we may also be able to identify how it is regulated in other cancers as well. Ultimately, the hope of this type of research is that necroptosis could represent a new Achille's heel for aggressive drug resistant cancers, opening the door to new approaches for treatment.
Competitiondate
201302
Approvedterm2
3 yrs 0 mth
Pinamesdelim
McComb, Scott R
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~